Amgen’s new genetically
engineered treatment Imlygic
(talimogene laherparepvec) for
unresectable metastatic melanoma
has been recommended to the
European Medicines Agency
(EMA) for marketing under specific
circumstances.
If it receives final approval it will
be a first in class novel agent to
receive marketing authorisation.The above article was sent to subscribers in Pharmacy Daily's issue from 27 Oct 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Oct 15
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.